IBD-Associated Arthritis News

Johns Hopkins Hospital has been recognized by U.S. News & World Report’s Best Hospitals Survey as the top-ranked hospital in the country for rheumatology for the 2018 to 2019 year.

Healio Rheumatology is proud to announce the launch of Rheuminations, a podcast series hosted by Adam Brown, MD, focusing on medical mysteries and other ripping yarns of the immune system gone awry.

Sandoz received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for its proposed adalimumab biosimilar for the treatment of all indications of its reference product, including rheumatoid arthritis, plaque psoriasis, Crohn's disease and ulcerative colitis, according to a manufacturer release.

BOSTON — Advances in the understanding of epigenetic modifications — changes in gene activity without changes in DNA sequencing — could lead to the development of new biomarkers and potential therapies for immune-modulated inflammatory diseases, according to a presentation given at the Interdisciplinary Autoimmune Summit.

BOSTON — Rheumatologists, gastroenterologists, dermatologists, immunologists and other health care providers who care for patients with immune-mediated inflammatory diseases will gather at the Interdisciplinary Autoimmune Summit in Boston this weekend for a collaborative discussion of treatment strategies.

Following the implementation of standardized protocols for intravenous therapy use at a pediatric rheumatology infusion center, only 1.9% of all infusions were associated with adverse events, according to findings published in Pediatric Rheumatology.

Samsung Bioepis and Abbvie have reached a global settlement agreement regarding the commercialization of SB5, the proposed adalimumab biosimilar for Humira, according to a press release.

Patients with arthritis who are younger, have rheumatoid factor positivity and demonstrate higher disease activity at baseline are at an increased risk for experiencing methotrexate failure due to inefficacy, according to findings published in Arthritis Care & Research.

Sandoz received a positive opinion the European Medicines Agency’s Committee for Medicinal Products for Human Use for its proposed infliximab biosimilar for the treatment of all indications of its reference product across rheumatology, dermatology and gastroenterology, according to a manufacturer release.

The use of biologic medications for autoimmune diseases prior to or during pregnancy is not associated with an increased risk for preterm delivery or infants that are small for gestational age, according to findings published in the Annals of the Rheumatic Diseases.